IKZF1 and neoplasm: However, it is possible that an increased dosage or more frequent treatments with API, may lead to a significant decrease in CK2 activity, which could lead to the up-regulation and the stability of more full-length Ikaros isoforms and consequently an increase in anti-tumor immune responses.